Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

被引:7
|
作者
Ventura, Yossi [1 ,2 ]
Carr, Brian I. [3 ]
Kori, Issac [4 ]
Guerra, Vito [5 ]
Shibolet, Oren [1 ,2 ]
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Hepatol, Liver Unit, 14 Weizman St, IL-62431 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey
[4] Tel Aviv Med Ctr & Sch Med, Div Imaging, Intervent Radiol, IL-62431 Tel Aviv, Israel
[5] IRCCS Bellis, Dept Clin Trials & Epidemiol, I-70013 Castellana Grotte, Italy
关键词
Hepatocellular carcinoma; Aggressiveness index; Liver function; Transarterial chemoembolization; Survival; GAMMA-GLUTAMYL-TRANSPEPTIDASE; PREDICT SURVIVAL; PROGNOSTIC VALUE; SCORES; EMBOLIZATION; INDEX;
D O I
10.3748/wjg.v24.i15.1641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate novel predictors of survival in hepatocellular carcinoma (HCC) patients following transarterial chemoembolization (TACE). METHODS One hundred sixty seven patients with un-resectable HCC were retrospectively analyzed to identify factors that might contribute to their HCC biology and aggressiveness. We correlated routine laboratory results (total bilirubin, AST, ALKP, GGTP, albumin etc.) to maximum tumor diameter, number of tumor nodules, portal vein thrombosis and blood alpha-fetoprotein levels. These 4 parameters were previously combined to form an aggressiveness index (AgI). We used The Wilcoxon ranksum (Mann-Whitney), to test the correlation between the AgI categories and liver function parameters. The Cox proportional hazards model was applied to evaluate the categories of AgI associated with overall survival. RESULTS The AgI was strongly correlated with survival in this novel patient population. Three year survival probability for AgI > or < 4 was 42.4% vs 61.8%; p < 0.0863 respectively. Several factors independently correlated with AgI using univariate multiple logistic regression of AgI with 8 laboratory parameters. Lower albumin levels had an OR of 2.56 (95% CI: 1.120-5.863 p < 0.026), elevated Alkaline phosphatase and gamma glutamyl transpeptidase (GGTP) had ORs of 1.01 (95% CI: 1.003-1.026, p < 0.017) and 0.99 (95% CI: 0.99-1.00, p < 0.053) respectively. In a Cox proportional hazard model combining mortality for AgI score and liver function parameters, only GGTP levels and the AgI were independently associated with survival. An AgI > 4 had HR for mortality of 2.18 (95% CI: 1.108-4.310, p < 0.024). GGTP's single unit change had a HR for mortality of 1.003 (95% CI: 1.001-1.006, p < 0.016). These were considered in the final multivariate model with the total cohort. An AgI > 4 had a HR for mortality of 2.26 (95% CI: 1.184-4.327, p < 0.016). GGTP had a HR of 1.003 (95% CI: 1.001-1.004, p < 0.001). CONCLUSION Our study validates the AgI in a new population with un-resectable HCC patients undergoing TACE. The analysis establishes a correlation between GGTP and the AgI.
引用
收藏
页码:1641 / 1649
页数:9
相关论文
共 50 条
  • [21] Transarterial chemoembolization for hepatocellular carcinoma
    Lau, WY
    Yu, SCH
    Lai, ECH
    Leung, TWT
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 202 (01) : 155 - 168
  • [22] TRANSARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA
    Vremera, Teodora
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2013, 117 (01): : 182 - 182
  • [23] Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: An Australian multicenter cohort study
    Mishra, G.
    Dev, A.
    Paul, E.
    Roberts, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 93 - 94
  • [24] Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study
    Huo, TI
    Wu, JC
    Lee, PC
    Chang, FY
    Lee, SD
    LIVER INTERNATIONAL, 2004, 24 (03) : 210 - 215
  • [25] Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Megan E. McNally
    Antonio Martinez
    Hooman Khabiri
    Gregory Guy
    Anthony J. Michaels
    James Hanje
    Robert Kirkpatrick
    Mark Bloomston
    Carl R. Schmidt
    Annals of Surgical Oncology, 2013, 20 : 923 - 928
  • [26] Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Fan, Mi
    Niu, Tingting
    Lin, Binwei
    Gao, Feng
    Tan, Bangxian
    Du, Xiaobo
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 20 (03)
  • [27] Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Jung, Eun Suk
    Kim, Ji Hoon
    Yoon, Eileen L.
    Lee, Hyun Jung
    Lee, Soon Jae
    Suh, Sang Jun
    Lee, Beom Jae
    Seo, Yeon Seok
    Yim, Hyung Joon
    Seo, Tae-Seok
    Lee, Chang Hee
    Yeon, Jong Eun
    Park, Jong-Jae
    Kim, Jae Seon
    Bak, Young Tae
    Byun, Kwan Soo
    JOURNAL OF HEPATOLOGY, 2013, 58 (06) : 1181 - 1187
  • [28] Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index
    Mueller, Lukas
    Hahn, Felix
    Maehringer-Kunz, Aline
    Stoehr, Fabian
    Gairing, Simon Johannes
    Michel, Maurice
    Foerster, Friedrich
    Weinmann, Arndt
    Galle, Peter Robert
    Mittler, Jens
    Pinto dos Santos, Daniel
    Pitton, Michael Bernhard
    Dueber, Christoph
    Kloeckner, Roman
    CANCERS, 2021, 13 (19)
  • [29] Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    McNally, Megan E.
    Martinez, Antonio
    Khabiri, Hooman
    Guy, Gregory
    Michaels, Anthony J.
    Hanje, James
    Kirkpatrick, Robert
    Bloomston, Mark
    Schmidt, Carl R.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (03) : 923 - 928
  • [30] Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Espejo-Cruz, Maria L.
    Gonzalez-Rubio, Sandra
    Espejo, Juan J. J.
    Zamora-Olaya, Javier M. M.
    Alejandre-Altamirano, Rafael M. M.
    Prieto-Torre, Maria
    Linares, Clara I. I.
    Guerrero-Misas, Marta
    Barrera-Baena, Pilar
    Poyato-Gonzalez, Antonio
    Sanchez-Frias, Marina
    Ayllon, Maria D.
    Rodriguez-Peralvarez, Manuel L. L.
    de la Mata, Manuel
    Ferrin, Gustavo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)